Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Sep 23, 2026Reported sale · Form 4Akos Czibere, Chief Medical Officer · $103.0KOpen the filing ↗
- Sep 23, 2026Reported sale · Form 4Akos Czibere, Chief Medical Officer · $155.6KOpen the filing ↗
- Sep 23, 2026Notice of sale · Form 144Akos Czibere · Officer · $552.8KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year173
SEC filings on record525 flagged findings
Reported transactions (Form 4)76since Jan 12, 2026 · and 40 other holdings
Corporate events (8-K)1since Apr 16, 2026
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Reverse splits in 5 years
1 reverse split in 5 years (1:3.8 on Feb 1, 2026) · 1:3.8 cumulative
The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).
Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.
The 25 most recent filings (of 52)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Sep 24, 26Form 4 ↗Insider transaction
- Sep 23, 26Form 144 ↗Notice of proposed sale
- Aug 13, 2610-Q ↗Quarterly report
- Aug 13, 268-K ↗Current report · Results
- Jul 21, 26Form 4 ↗Insider transaction
- Jul 20, 26Form 144 ↗Notice of proposed sale
- Jul 20, 26Form 4 ↗Insider transaction
- Jul 17, 26Form 144 ↗Notice of proposed sale
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Jul 8, 26Form 144 ↗Notice of proposed sale
- Jul 8, 26Form 144 ↗Notice of proposed sale
- May 14, 26SCHEDULE 13G ↗Passive stake · Blue Owl Capital Holdings LP · 5.9% · event on Mar 31, 26
- May 11, 2610-Q ↗Quarterly report
- May 11, 268-K ↗Current report · Results
- Apr 16, 26Form 4 ↗Insider transaction
- Apr 16, 26Form 3 ↗Insider transaction
- Apr 16, 268-K ↗Current report · A senior executive left or was appointed
- Mar 30, 268-K ↗Current report · Results
- Mar 30, 2610-K ↗Annual report
- Jan 20, 26SCHEDULE 13D ↗Stake with intent to influence · ANSBERT GADICKE · 19.3% · event on Jan 12, 26
- Jan 20, 26SCHEDULE 13D ↗Stake with intent to influence · EcoR1 Capital, LLC · 9.1% · event on Jan 12, 26
- Jan 15, 26SCHEDULE 13D ↗Stake with intent to influence · Eli Lilly and Company · 11.9% · event on Jan 12, 26
- Jan 15, 26Form 3 ↗Insider transaction
- Jan 14, 26Form 4 ↗Insider transaction
52 filings on record, the oldest from Dec 19, 25.
Listing the 25 most recent filings of the 52 on record.
1
- Apr 16, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- ANSBERT GADICKE19.3%Jan 12, 26SCHEDULE 13D ↗13 co-filers on this document — the figure is the largest single stake, not their sum.
- Eli Lilly and Company11.9%Jan 12, 26SCHEDULE 13D ↗
- VV Manager II LLC10.9%Jan 12, 26SCHEDULE 13D ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
- EcoR1 Capital, LLC9.1%Jan 12, 26SCHEDULE 13D ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- Blue Owl Capital Holdings LP5.9%Mar 31, 26SCHEDULE 13G ↗
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Sep 23, Akos Czibere filed notice of intent to sell up to $553K. That is about 0.05% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $259K across 2 trades on Sep 23, per their Form 4. That is 50% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+4 more recent notices · 4 with a later sale
- Sep 23, 26Sell$103KAkos CzibereChief Medical Officer↗
- Sep 23, 26Sell$156KAkos CzibereChief Medical Officer↗
- Jul 20, 26Sell$86KKen Herrmann↗
- Jul 20, 26Sell$33KKen Herrmann↗
- Jul 17, 26Sell$77KKen Herrmann↗
- Jul 8, 26Sell$401KAkos CzibereChief Medical Officer↗
- Jul 8, 26Sell$862KAkos CzibereChief Medical Officer↗
- Jul 8, 26Sell$125KAkos CzibereChief Medical Officer↗
- Jul 8, 26Sell$429KShulamit Ron-BiggerChief Operating Officer↗
- Jul 8, 26Sell$838KShulamit Ron-BiggerChief Operating Officer↗
- Jul 8, 26Sell$121KShulamit Ron-BiggerChief Operating Officer↗
- Jan 12, 26Buy$37.4MEcoR1 Capital, LLC↗
There are 7 more transactions in this stretch.
Stock compensation, tax and giftsshow the 21 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 23, 26Compensation$62KAkos CzibereChief Medical Officer↗
- Jul 20, 26Compensation$280Ken Herrmann↗
- Jul 20, 26Compensation$3KKen Herrmann↗
- Jul 17, 26Compensation$245Ken Herrmann↗
- Jul 8, 26Compensation$248KAkos CzibereChief Medical Officer↗
- Jul 8, 26Compensation$183KShulamit Ron-BiggerChief Operating Officer↗
- Jan 12, 26Otheramount n/aEcoR1 Capital, LLC↗
- Jan 12, 26Otheramount n/aEcoR1 Capital, LLC↗
- Jan 12, 26Otheramount n/aEcoR1 Capital, LLC↗
- Jan 12, 26Otheramount n/aHelen Susan Kim↗
- Jan 12, 26Otheramount n/aHelen Susan Kim↗
- Jan 12, 26Otheramount n/aLloyd Mitchell Segal↗
- Jan 12, 26Otheramount n/aVida Ventures II, LLC↗
- Jan 12, 26Otheramount n/aVida Ventures II, LLC↗
- Jan 12, 26Otheramount n/aANSBERT GADICKE↗
- Jan 12, 26Otheramount n/aANSBERT GADICKE↗
- Jan 12, 26Otheramount n/aANSBERT GADICKE↗
- Jan 12, 26Otheramount n/aMPM BIOVENTURES 2018, L.P.↗
- Jan 12, 26Otheramount n/aMPM BIOVENTURES 2018, L.P.↗
- Jan 12, 26Otheramount n/aMPM BIOVENTURES 2018, L.P.↗
- Jan 12, 26Otheramount n/aTodd Foley↗
The full record holds 43 transactions and goes back to Jan 8, 26.
Its sector and its market
Aktis Oncology, Inc. among Information Technology companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Information Technology companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Aktis Oncology, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Aktis Oncology, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 52 documents on file, from Dec 19, 2025 to Sep 24, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.